We partner with 1Cell.Ai to bring next-generation cancer diagnostics to the region, with a focus on the Comprehensive Tissue-Liquid-Normal Match genomic test — an advanced approach that integrates molecular profiling of both tumor and normal samples.
By combining advanced molecular science with Artificial Intelligence technology, 1Cell.Ai enables earlier detection, personalized treatment decisions, and real-time monitoring — empowering clinicians to deliver precision care with confidence.
Among 1Cell.Ai’s broad portfolio, we spotlight three flagship solutions that exemplify their impact in advancing cancer diagnostics and transforming patient outcomes.
An integrated tissue–liquid–normal DNA test delivering somatic, germline, and CHIP classification in one assay. OncoIndx® Prime+ combines NGS, RNA fusion detection, and pharmacogenomics to support complex oncology cases.
A liquid biopsy test for longitudinal cancer monitoring, using CTC and ctDNA analysis to track treatment response, detect resistance, and identify minimal residual disease (MRD). Ideal for real-time, non-invasive follow-up.
A cost-effective targeted NGS test covering guideline-recommended genes for major cancers like breast, lung, and colon. OncoTarget® enables personalized therapy decisions using deep sequencing and customizable gene panels.